PO.CL05.04 · 临床研究

研究B7-H7介导的NK细胞活性激活的转录组特征

Investigating the transcriptomic signature of B7-H7-mediated activation of NK cell activity

海报缩略图:研究B7-H7介导的NK细胞活性激活的转录组特征
编号 6559 展板 25 时间 4/21 02:00–05:00 区域 Section 44 主讲 Michael Gomez, BA
分会场 Immune Checkpoint Blockade
查看 PDF 下载 PDF 🔒 查看 / 下载完整 PDF 需登录并开通下载套餐 · 查看套餐 / 开通 AACR 官方页面

作者与单位 Authors & Affiliations

Michael Gomez1, Deepthi Chowbene2, Nahuel Perrot2, Nikolaos Kalavros2, Shuoshuo Wang2, Antonella Arruda de amaral2, David F. McDermott3, Gordon J. Freeman1, Ioannis S. Vlachos2, Kathleen M. Mahoney2

1Dana-Farber Cancer Institute, Boston, MA,2Beth Israel Deaconess Medical Center, Boston, MA,3Beth Israel Deaconess Medical Center, Milton, MA

摘要 Abstract

中文摘要
确定靶向免疫检查点的抗体如何改变淋巴细胞功能,可以增进我们对患者免疫检查点抑制剂应答的理解。HERV-H LTR相关蛋白2(HHLA2,B7-H7)是一种由多种肿瘤表达的免疫检查点。我们团队此前发现B7-H7除了具有激活性受体TMIGD2外,还有一个抑制性受体KIR3DL3。这两种B7-H7受体均由T细胞和NK细胞亚群表达。然而,对于不同淋巴细胞亚群如何受到B7-H7与这些受体结合的影响知之甚少,而目前多种B7-H7:KIR3DL3阻断抗体正在I期临床试验中招募癌症患者(NCT05824663、NCT06240728)。在本研究中,我们通过单细胞RNA测序(scRNAseq)在体外探究了表达B7-H7的肿瘤对NK细胞的影响。从外周血中分离NK细胞,并与K562细胞或过表达B7-H7的K562细胞共培养2小时。共培养在不同B7-H7阻断抗体或同型对照存在的情况下进行。133,017个细胞通过质量控制,鉴定出9个不同的NK细胞群体。未与肿瘤细胞共培养的原代NK细胞主要由两个TXNIP+ CD96高表达的NK细胞簇组成,它们的细胞毒性和炎症基因表达较低。此外,这两个簇的TMIGD2表达最高,提示这些群体代表静息NK细胞。与K562或K562-B7-H7细胞共培养增加了高细胞毒性和炎症性NK细胞簇的比例。然而,与K562-B7-H7共培养的NK细胞中XCL2、CSF2、IFNgamma和IL3高于与K562共培养的NK细胞,提示K562细胞上的B7-H7在此早期激活模型中具有促炎作用。值得注意的是,仅有一小部分外周血NK细胞表达抑制性受体KIR3DL3,这与早期NK激活的预期一致。此外,与不含抗体培养的NK细胞相比,所有抗体处理(无论Fc同型如何)均与CRTAM+ IL2RA+ TNFRSF9+ NK细胞簇比例增加相关。B7-H7抗体克隆6F10和2C4按各自Fc(IgG1或IgG4)进行的差异基因表达分析提示,用双受体阻断B7-H7抗体(6F10)阻断TMIGD2会降低NK细胞的激活程度,而阻断KIR3DL3但不阻断TMIGD2的B7-H7抗体(2C4)则不然。我们的工作提示,选择能够保留B7-H7:TMIGD2相互作用的B7-H7疗法对于维持B7-H7表达所带来的任何NK依赖性抗肿瘤益处具有重要意义。
查看英文原文 English abstract
Determining how antibodies that target immune checkpoints alter lymphocyte functions can improve our understanding of immune checkpoint inhibitors responses in patients. HERV-H LTR-associating 2 (HHLA2, B7-H7) is an immune checkpoint expressed by many tumors. Our group previously found that B7-H7 has an inhibitory receptor, KIR3DL3, in addition to having an activating receptor, TMIGD2. Both B7-H7 receptors are expressed by subsets of T cells and NK cells. However, little is known about how different subsets of lymphocytes are affected by B7-H7 engagement of these receptors, and multiple B7-H7:KIR3DL3 blocking antibodies are currently enrolling cancer patients in Phase I clinical trials (NCT05824663, NCT06240728).In this study, we explored the effect of tumors expressing B7-H7 on NK cells in vitro by single cell RNA sequencing (scRNAseq). NK cells were isolated from peripheral blood and co-cultured with K562 cells or K562 cells overexpressing B7-H7 for 2hr. Co-cultures were performed in the presence of different B7-H7 blocking antibodies or isotype controls. 133,017 cells passed quality control, with 9 distinct NK cell populations being identified. Primary NK cells not co-cultured with tumor cells were mainly composed of two TXNIP+ CD96 hi NK cell clusters that had low expression of cytotoxic and inflammatory genes. Additionally, these two clusters had the highest expression of TMIGD2, suggesting that these populations represent resting NK cells. Co-culture with K562 or K562-B7-H7 cells increased the proportion of highly cytotoxic and inflammatory NK cell clusters. However, XCL2, CSF2, IFNgamma and IL3 were higher in NK cells co-cultured with K562-B7-H7 than with K562, suggesting B7-H7 on K562 cells is proinflammatory in this early activation model. Notably, only a small subset of peripheral blood NK cells expressed the inhibitory receptor KIR3DL3, as expected in early NK activation. Furthermore, all antibody treatments regardless of the Fc isotype were associated with increased proportions of CRTAM+ IL2RA+ TNFRSF9+ NK cell clusters, compared to NK cells cultured without antibody. Differential gene expression analysis between B7-H7 antibody clones 6F10 and 2C4 by respective Fc (IgG1 or IgG4) suggested blocking TMIGD2 with the dual receptor blocking B7-H7 antibody (6F10) reduces the extent of activation of the NK cells compared to the B7-H7 antibody (2C4) that blocks KIR3DL3 but not TMIGD2.Our work suggests the importance of selecting B7-H7 therapeutics that spare the interaction of B7-H7:TMIDG2 to maintain any NK-dependent antitumor benefit of B7-H7 expression.
利益披露 Disclosure
M. Gomez, None.. N. Perrot, None.. N. Kalavros, None. K. M. Mahoney, Nextpoint Theraputics ).

← 返回 AACR 2026 检索